Epitopea logo — Exploiting a new class of tumour specific antigens for cance...

Epitopea

Exploiting a new class of tumour specific antigens for cancer therapy

Founded 2021 Canada Montreal, Canada 50 employees Seed Total: $44.60M Biotechnology, Health and Wellness +1

General Information

Company Name Epitopea
Founded Year 2021
Location Canada Montreal, Canada +2
Employees 50
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Seed
Social

Get notified when Epitopea moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Epitopea

Epitopea, founded in 2021, is a promising player in the Biotechnology, Health and Wellness, and Life Sciences sectors, headquartered in Canada. The company is pioneering cancer therapy by exploiting a novel class of tumor-specific antigens. With the slogan, "Exploiting a new class of tumour specific antigens for cancer therapy," Epitopea aims to revolutionize the approach to cancer treatment through its innovative therapeutics.

The company's recent funding round, totaling a substantial $31.00M, showcases strong investor confidence. Key investors include renowned names like Advent Life Sciences, Cambridge Innovation Capital, and adMare BioInnovations, among others. This significant backing signals potential growth and breakthroughs in their targeted therapies.

As an emerging player, Epitopea is well-positioned to leverage its novel technologies to make significant impacts in the realm of cancer treatment, attracting attention from those looking to invest in transformative health innovations.

Taxonomy: cancer therapy, tumour-specific antigen, therapeutics development, oncology, immunotherapy, clinical trials, biomarker, cancer treatment, antigen targeting, precision medicine

Services & Products

Development of off-the-shelf RNA-based cancer immunotherapies
Identification of shared aberrantly expressed tumor-specific antigens
Creation and optimization of Cryptomap platform

Target Customers

Cancer patients Healthcare providers Cancer research institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 10
Investor Investor Investor Investor Investor Investor Investor
•••• ••••
01 Oct 2024
Seed •••••• 6
Investor Investor Investor Investor Investor
•••• ••••
01 Apr 2022

Epitopea Alternatives & Competitors

View All Alternatives
Epitopea vs

Biotechnology startup developing Tune & Track platform to expand utility & improve safety of CAR T t...

Series A
5 employees
Epitopea vs
Immunowake, Inc.
Immunowake, Inc. United States

Immunowake Inc. is a private, pre-clinical stage biotechnology company focused on cancer drug discov...

Series A
2 employees
Biotechnology
Epitopea vs

Exploring advanced techniques for antigen delivery in modern medicine.

Angel
4 employees
Biotechnology, Manufacturing

FAQ About Epitopea

Exploiting a new class of tumour specific antigens for cancer therapy
Epitopea was founded in 2021.
Epitopea is headquartered in Montreal, Canada.
Epitopea operates in the following industries: Biotechnology, Health and Wellness, Life Sciences.
Epitopea has approximately 50 employees.
Epitopea has completed 2 funding rounds, raising a total of $44.60M. The latest funding stage is Seed.
Epitopea offers: Development of off-the-shelf RNA-based cancer immunotherapies, Identification of shared aberrantly expressed tumor-specific antigens, Creation and optimization of Cryptomap platform.
Top alternatives and competitors to Epitopea include AffyImmune Therapeutics, Immunowake, Inc., Vaccizone, Greywolf Therapeutics, Cybrexa Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Epitopea and AffyImmune Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Epitopea and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy